Form 4: Shattuck Labs Officer Sells Shares Under 10b5-1 Plan

Shattuck Labs Chief Medical Officer, Arundathy N. Pandite, sold 30,000 shares of common stock for approximately $7.01 per share under a pre-established Rule 10b5-1 trading plan.

Summary

• Arundathy N. Pandite, Chief Medical Officer at Shattuck Labs, Inc., reported a transaction involving the sale of 30,000 shares of common stock.
• The sale occurred on June 30, 2026, and was executed under a Rule 10b5-1 trading plan established on February 2, 2026.
• The shares were sold at a weighted average price of $7.01, with individual transactions ranging from $6.62 to $7.40.
• Following this transaction, Pandite beneficially owns 136,219 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant share sale by a key executive, despite being executed under a Rule 10b5-1 plan, which can raise concerns about insider confidence.

Negatives

• A significant number of shares (30,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale occurred under a pre-arranged plan, suggesting a predetermined exit strategy rather than a reaction to current company performance.

Risks

• The sale of a substantial number of shares by an executive could signal a lack of confidence in the company's near-term prospects, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the sale reduces the executive's direct stake in the company, which may be viewed as a negative by some stakeholders.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider sales, even under a Rule 10b5-1 plan, are closely watched by the market. While such plans are designed to avoid insider trading concerns, significant sales by key executives can still influence investor perception and stock price, especially in the biotechnology sector where sentiment can be volatile.

Stakeholder Impact

• Shareholders: May view the sale as a negative signal, potentially impacting stock price, despite the Rule 10b5-1 plan.
• Employees: May interpret the sale as a sign of reduced confidence from management.
• Management: The executive continues to hold a substantial number of shares, indicating continued commitment.

Key Dates

Recommendation

The filing reports an insider sale under a pre-arranged plan, which is a common and often neutral event. While it reduces the executive's direct holdings, it does not provide new information about the company's performance or future prospects that would warrant a strong buy or sell recommendation. Therefore, a 'hold' position is appropriate pending further company updates.

Keywords

Shattuck Labs, STTK, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Beneficial Ownership